VIVAZEN® Urges Immediate Action on 7-OH as U.S. House of Representatives Examines End Needless Distribution of 7-OH Act

Key Takeaways

• House subcommittee holds hearing on H.R. 8000 targeting 7‑OH
• VIVAZEN urges DEA to schedule synthetic 7‑OH immediately
• Synthetic 7‑OH linked to toxicity, dependence, market confusion
• VIVAZEN’s kratom extracts showed no severe adverse events in study
• Scheduling would safeguard consumers and legit botanical supplement market

Summary

VIVAZEN® welcomed a House Energy and Commerce subcommittee hearing on H.R. 8000, the End Needless Distribution of 7‑OH Act, urging the DEA to promptly schedule the synthetic opioid 7‑hydroxymitragynine. The company highlighted public‑health risks such as toxicity, dependence and market confusion caused by products containing synthetic or highly concentrated 7‑OH. VIVAZEN emphasized its own GMP‑manufactured botanical supplements and a double‑blind clinical study showing no severe adverse events from its kratom extracts. It called for swift federal action to protect consumers and level the playing field for responsible manufacturers.

Pulse Analysis

The synthetic opioid 7‑hydroxymitragynine, known as 7‑OH, has emerged from laboratory processes rather than traditional kratom harvesting, raising alarm among regulators and health officials. Unlike naturally occurring alkaloids, 7‑OH can be produced at high potency, increasing the risk of overdose and dependence. Recent congressional scrutiny, embodied in H.R. 8000, reflects growing bipartisan concern that unregulated distribution threatens both public safety and the integrity of the broader dietary‑supplement ecosystem.

For legitimate botanical firms like VIVAZEN, the presence of 7‑OH in the marketplace creates an uneven competitive landscape. Companies adhering to Good Manufacturing Practices, third‑party testing, and transparent labeling face higher costs, while unscrupulous operators can profit from cheap, synthetic analogues that skirt existing regulations. VIVAZEN’s own double‑blind, placebo‑controlled trial of its kratom extract demonstrated no severe adverse events over a 28‑day period, underscoring the company’s commitment to evidence‑based wellness. By urging the DEA to act swiftly, VIVAZEN aims to protect consumers from hidden synthetic additives and preserve the credibility of responsibly sourced botanicals.

A definitive scheduling decision would provide regulatory clarity, enabling the FDA and law‑enforcement agencies to enforce bans on 7‑OH‑laden products nationwide. This move could curb illicit supply chains, reduce emergency‑room visits linked to synthetic opioid exposure, and encourage investment in high‑quality, science‑backed botanical research. As the market evolves, clear federal guidance will be essential for fostering innovation while ensuring that wellness products remain safe, trustworthy, and compliant with evolving drug‑control statutes.